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Annex, 14445 Olive View Drive, Sylmar, CA 91342, Abstract—Background: Patients with acute bacterial
skin and skin structure infections (ABSSSI) commonly pres-
ent to Emergency Departments (EDs) where physicians en-
counter a wide spectrum of disease severity. The
prevalence of community-acquired methicillin-resistant
Staphylococcus aureus (CA-MRSA) has increased in the
past decade, and CA-MRSA is now a predominant cause
of purulent ABSSSI in the United States (US). Objectives:
This article reviews significant developments since the
most recent Infectious Diseases Society of America (IDSA)
guidelines for the management of ABSSSI in the CA-
MRSA era, focusing on recent studies and recommendations
for managing CA-MRSA, newer antimicrobials with im-
provedMRSA activity, new diagnostic technologies, and op-
tions for outpatient parenteral antimicrobial therapy
(OPAT). Discussion: The increasing prevalence of CA-
MRSA has led the IDSA and other organizations to recom-
mend empiric coverage of CA-MRSA for purulent ABSSSI.
The availability of rapid MRSA detection assays from skin
and soft tissue swabs could potentially facilitate earlier se-
lection of targeted antimicrobial therapy. Several newer in-
travenous antibiotics with expanded MRSA coverage,
including ceftaroline fosamil, daptomycin, linezolid, and te-
lavancin, may be utilized for treatment of ABSSSI. OPAT
may be an option for intravenous administration of antibi-
otics in selected patients and may prevent or shorten hospi-
talizations, decrease readmission rates, and reduce
nosocomial infections and complications. Conclusion: Thene 2012;
vember 2012
e397growing prevalence of CA-MRSA associated with ABSSSI
in the US has a significant impact on clinical management
decisions in the ED. Recent availability of new diagnostic
testing and therapeutic options may help meet the demand
for effective antistaphylococcal agents.  2013 Elsevier
Inc.
, Keywords—CA-MRSA; cellulitis; abscess; infection; an-
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INTRODUCTION
Patients in the United States (US) with acute bacterial
skin and skin structure infections (ABSSSI), previously
referred to as uncomplicated and complicated skin and
skin structure infections, commonly present to Emer-
gency Departments (EDs). A wide spectrum of disease
severity, ranging from mild cellulitis to serious life-
threatening necrotizing infections, may be encountered
in this setting (1). The mechanisms of injury for wound
infections vary from animal bites to gunshot wounds,
and in most cases, empiric antibiotic therapy must be ini-
tiated before culture and susceptibility results are avail-
able. ABSSSI are primarily caused by Gram-positive
pathogens, including Staphylococcus aureus and Strepto-
coccus pyogenes, as well as certain Gram-negative and
anaerobic bacteria, particularly with polymicrobial
Figure 1. Annual visits to United States Emergency Depart-
ments for selected acute bacterial skin and skin structure
infections (ABSSSI) during the emergence of community-
acquired methicillin-resistant Staphylococcus aureus
(CA-MRSA), 1993–2005, and proportion of antibiotic regi-
mens active against CA-MRSA (reproduced from reference
14, with permission). *ABSSSI commonly causedbyS. aureus
were included in the case definition and were defined by the
International Classification of Diseases, 9th Revision, Clinical
Modification codes for: cellulitis and abscess of finger or toe;
other cellulitis and abscess (which includes head, neck,
trunk, limbs, and buttocks); cellulitis digit not otherwise
specified; felon; impetigo; hidradenitis; other specified dis-
eases of the hair and hair follicle (i.e., folliculitis); infective
mastitis; nonpurulent mastitis; breast abscess; or carbuncle
and furuncle. yAn antibiotic regimen was considered
‘‘active against CA-MRSA’’ if it contained trimethoprim-
sulfamethoxazole, tetracycline, doxycycline, clindamycin,
rifampin, linezolid, or vancomycin, although resistance to
some of these agents does occur. Before 2002, too few pre-
scriptions included an anti-CA-MRSA agent for robust esti-
mates.
e398 G. J. Moran et al.infections (2–5). Before the year 2000, methicillin-
resistant S. aureus (MRSA) was a rare pathogen in
community-acquired (CA) infections and was more com-
mon in nosocomial infections (6,7). However, the
prevalence of CA-MRSA has increased greatly in the
past decade, and CA-MRSA is now a predominant cause
of purulent ABSSSI in the US (8–16).
Infections from MRSA more than doubled during
a 5-year period in patients who presented with purulent
ABSSSI to a Los Angeles ED, increasing from 29% in
2001 to 64% in 2005 (12). Data from the SENTRYAnti-
microbial Surveillance Program evaluating causes of var-
ious types of skin and soft tissue infections between 1998
and 2004 indicated that S. aureus was a dominant patho-
gen globally and accounted for 44.6% of isolates in North
America; 35.9% of the isolates were methicillin resistant
(5). Although the global epidemiology of CA-MRSA is
heterogenous, with multiple clones in some regions,
USA300 is the most common strain in community-
associated infections in the US (13,15,17–19). Unlike
nosocomial or health care-associated strains, CA-
MRSA tends to be more virulent and may carry genes
that encode the Panton-Valentine leukocidin, a leukotoxin
associated with tissue necrosis and more severe disease(18,20–22). No clinical or epidemiologic risk factors
reliably distinguish CA-MRSA from other pathogens,
and CA-MRSA skin infections range from simple cutane-
ous abscesses to fulminant necrotizing fasciitis
(1,2,13,23). Although the rate of treatment failures for
ABSSSI remains relatively low in the ED, failures are
more likely to occur with S. aureus infections (24).
The predominance of CA-MRSA correlates with a dra-
matic increase in ED visits and hospitalizations in both
adult and pediatric patients presenting with ABSSSI
(14,15,25,26). Data from the National Hospital
Ambulatory Medical Care Survey (NHAMCS) indicate
that the annual number of ED visits for ABSSSI nearly
tripled since surveillance began in 1993, increasing to
3.4 million visits by 2005 (Figure 1) (14). Another study
showed that total hospital admissions for ABSSSI in-
creased by 29% between 2000 and 2004, with the greatest
number of admissions among younger patients (age < 65
years) and those with superficial infections (e.g., celluli-
tis, abscess) (27).
When the Infectious Diseases Society of America
(IDSA) prepared their 2005 guidelines on the manage-
ment of skin and soft tissue infections, the role of CA-
MRSA was not yet recognized, and therefore, empiric
treatment of this organism was not recommended (28).
In response to the significance of CA-MRSA as a patho-
gen in ABSSSI, the IDSA and other organizations cur-
rently recommend coverage of CA-MRSA for ABSSSI,
including purulent cellulitis (29). There is evidence that
Emergency Physicians have adopted this and include an-
tibiotics with expanded MRSA activity in the manage-
ment of ABSSSI (1,13–15,30,31). Compared with data
from an earlier survey conducted in 2004, the
prevalence of MRSA as a cause of purulent ABSSSI
remained stable (59% in both study periods), but
physicians’ prescribing patterns significantly changed
(13). Antibiotic therapy was discordant with susceptibil-
ity testing in 57% (100/175) of patients withMRSA infec-
tions who received antibiotics in 2004 (13). By 2008,
there was a shift from empiric therapy with b-lactams
that lackedMRSA activity to use of a MRSA-active agent
in 97% (310/318) of patients (15). Among hospitalized
patients, an agent with MRSA activity (primarily vanco-
mycin) was used in 90% (72/80) of patients in 2008, com-
pared with 46% (26/56) of patients in 2004. The
NHAMCS also noted a shift; whereas antibiotics active
against CA-MRSA were rarely used in 1993, by 2005,
38% of regimens included such agents (Figure 1) (14).
In light of the increase in CA-MRSA infections,
a group of Emergency Physicians met at a roundtable
meeting in San Francisco, California, on October 16,
2011 to discuss newer perspectives in the management
of ABSSSI. This article summarizes discussions from
the meeting and provides a review of significant
Table 1. Conditions in Which Antimicrobial Therapy is Recommended after Incision and Drainage of an Abscess Caused by
Community-acquired Methicillin-resistant Staphylococcus aureus (CA-MRSA)
1. Severe or extensive disease (e.g., involving multiple sites of infection) or rapid progression in presence of associated cellulitis
2. Signs and symptoms of systemic disease
3. Associated comorbidities or immunosuppression (diabetes mellitus, human immunodeficiency virus infection/acquired
immunodeficiency syndrome, neoplasm)
4. Extremes in age
5. Abscess in area difficult to drain completely (e.g., face, hand, genitalia)
6. Associated septic phlebitis
7. Lack of response to incision and drainage alone
Reproduced from reference (29), with permission.
Acute Bacterial Skin Infections e399developments since the 2005 IDSA guidelines for the
management of ABSSSI, including a review of recent
studies and recommendations for managing CA-MRSA,
newer antimicrobials with improved MRSA activity,
new diagnostic technologies, and options for outpatient
parenteral antimicrobial therapy (OPAT).
DISCUSSION
Guidelines in the CA-MRSA Era
The increasing prevalence of CA-MRSA impacts selec-
tion of empiric antibiotics for ABSSSI, emphasizing
use of agents with improved MRSA activity (14). This
change is reflected in recent treatment guidelines
(29,32–35). In 2011, IDSA published their first
guidelines specifically on the treatment of MRSA
infections, providing recommendations on management
of the most common clinical infections associated with
MRSA (29). IDSA recommended antimicrobial therapy
after incision and drainage of abscesses caused by CA-
MRSA (Table 1). For ABSSSI, IDSA recommendations
for empiric coverage of CA-MRSA in the outpatient set-
ting included (oral antibiotic options): clindamycin,
trimethoprim-sulfamethoxazole, a tetracycline (doxycy-
cline or minocycline), and linezolid. In hospitalized pa-
tients, IDSA suggested broad-spectrum antibiotics with
empiric agents that cover for MRSA pending culture re-
sults, including vancomycin, linezolid, daptomycin, tela-
vancin, and clindamycin. Due to the likelihood of
resistance development, rifampin is not recommended
for monotherapy in the treatment of MRSA infections.
The US Centers for Disease Control and Prevention pro-
vided similar recommendations for outpatient manage-
ment of ABSSSI (32). The 2011 Surgical Infection
Society guidelines for ABSSSI suggested that coverage
for CA-MRSA be considered in most settings for compli-
cated, non-necrotizing infections (abscesses) because
MRSA isolates equal or exceed methicillin-susceptible
S. aureus (MSSA) strains in surgical-site infections (33).
Vancomycin. Although vancomycin remains the most
common choice for parenteral treatment of CA-MRSAinfections in the US, evidence of resistance development
and decreased efficacy is emerging (29,34–38). Certain
intrinsic limitations of vancomycin, such as poor tissue
penetration, relatively slow bactericidal activity, and
susceptibility issues, may play a role in treatment
failures (39–41). Studies in diverse patient populations
(post-surgical, diabetics) indicate that vancomycin
tissue concentrations are variable (42). Although not
specifically in skin infections, patient outcomes have
been associated with vancomycin susceptibility, and
higher vancomycin minimum inhibitory concentrations
(MICs) may correlate with decreased overall treatment
success (37,41,43). Treatment failures and increased
morbidity have been reported with strains of S. aureus
with decreased vancomycin susceptibility (e.g.,
vancomycin-intermediate S. aureus [VISA],
vancomycin-heteroresistant S. aureus [hVISA], and
vancomycin-resistant S. aureus [VRSA]), leading to con-
cerns that clinical failures may be associated with gradual
loss of vancomycin activity (40,43,44). In recognition of
increasing staphylococcal MIC to vancomycin, in 2006
the Clinical and Laboratory Standards Institute (CLSI)
lowered vancomycin MIC breakpoints to #2 mg/L for
susceptible strains, 4–8 mg/L for intermediate strains,
and $16 mg/L for resistant strains (38). Despite these
changes, vancomycin ‘‘MIC creep’’ has been documented
in MRSA isolates characterized as susceptible by CLSI
criteria, and multi-drug-resistant strains of MRSA have
been reported (20,45). Considering poor tissue
penetration as a factor, small increases in MIC could
result in suboptimal vancomycin concentrations at
certain sites of infection.
In 2009, the American Society of Health-System Phar-
macists, the IDSA, and the Society of Infectious Diseases
Pharmacists jointly issued a consensus statement on the
therapeutic monitoring of vancomycin in adults (34,35).
The panel recommended vancomycin 15–20 mg/kg/
dose (based on actual body weight; not to exceed
2 g/dose) every 8 to 12 h, with a loading dose of 25–30
mg/kg considered for seriously ill patients with MRSA
infections. For severe infections, such as necrotizing
fasciitis caused by MRSA, higher vancomycin trough
Table 2. Characteristics of Newer Antimicrobials with Skin Indications (51–54)
Ceftaroline Fosamil (Teflaro) Daptomycin (Cubicin) Linezolid (Zyvox) Telavancin (Vibativ)
Indication(s) Treatment of the following infections
caused by designated susceptible
bacteria
 Acute bacterial skin and skin
structure infections (ABSSSI)
 Community-acquired
bacterial pneumonia (CABP)
 Complicated skin and skin
structure infections (cSSSI)
 Staphylococcus aureus blood-
stream infections (bacteremia),
including thosewith right-sided
infective endocarditis
Treatment of the following infections
caused by designated susceptible
bacteria
 Vancomycin-resistant
Enterococcus faecium
infections
 Nosocomial pneumonia
 Complicated skin and skin
structure infections,
including diabetic foot
infections, without
concomitant osteomyelitis
 Uncomplicated skin and skin
structure infections
 Community-acquired
pneumonia
 Complicated skin and skin structure
infections (cSSSI)
Dosage &
administration
(for skin infections)
 600 mg i.v. q12h infused over 1
h for 5–14 days in ABSSSI
 400 mg i.v. q12h infused over 1
h in patients with CrCL > 30 to
#50 mL/min; 300 mg i.v. q12h
if CrCL $ 15 to #30 mL/min;
200 mg i.v. q12 h in patients
with end-stage renal disease
(CrCL < 15 mL/min), including
hemodialysis
 4 mg/kg i.v. q24h over 0.5 h in
0.9% NaCl for 7–14 days in
cSSSI
 400 mg i.v. q12h infused over 1
h in patients with CrCL $ 10 to
#50 mL/min
 4 mg/kg (cSSSI) i.v. q24h in
patients with CrCL $ 30 mL/
min; 4 mg/kg (cSSSI) q48h for
CrCL < 30 mL/min,
including those on
hemodialysis
 600 mg i.v. or oral q12h for
10–14 days in cSSSI (adults
and adolescents $ 12 years)
 400 mg PO q12h for 10–14
days for uncomplicated skin
and skin structure infections
(adults)
 600 mg p.o. q12h for 10–14
days for uncomplicated skin
and skin structure infections
(adolescents $ 12 years)
 10mg/kg i.v. q24h infused over 1 h for 7–14
days
 7.5 mg/kg i.v. q24h infused over 1 h in pa-
tients with CrCL 30–50 mL/min; 10 mg/kg
i.v. q48h in patients with CrCL 10– <30 mL/
min
Use in pregnancy and
pediatrics
 Pregnancy category B
 It is not known if ceftaroline is
excreted in breast milk
 Safety and effectiveness in
pediatric patients have not
been established
 Pregnancy category B
 It is not known if daptomycin is
excreted in breast milk
 Safety and effectiveness in
patients under the age of
18 years have not been
established
 Pregnancy category C
 It is not known if linezolid is
excreted in breast milk
 Dosing for pediatric patients
(birth through 11 years of age)
is based on weight
 Pregnancy category C
 It is not known if telavancin is
excreted in breast milk
 The safety and effectiveness of
telavancin in pediatric patients has
not been studied
Most common adverse
events (AEs) ($2%)
 Diarrhea, nausea,
constipation, vomiting,
increased transaminases,
hypokalemia, rash, phlebitis
 Constipation, nausea,
injection-site reactions,
headache, diarrhea, insomnia,
rash, vomiting, abnormal liver
function tests, pruritus,
elevated CPK, fungal infection,
urinary tract infection,
hypotension, renal failure,
dizziness, anemia, dyspnea
 Diarrhea, headache,
nausea, vomiting, insomnia,
constipation, rash,
dizziness, fever (in adults)
 Taste disturbance, nausea, vomiting,
foamy urine, diarrhea, dizziness,
pruritus, rash, infusion-site pain,
rigors, generalized pruritus,
decreased appetite, infusion-site
erythema, abdominal pain
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Drug interactions  No clinical drug–drug
interaction studies have been
conducted to date
 There is minimal potential for
drug–drug interactions
between ceftaroline and
CYP450 substrates, inhibitors,
or inducers, drugs known to
undergo active renal secretion,
and drugs that may alter renal
blood flow
 The pharmacokinetics of
daptomycin were not altered
after coadministration with
aztreonam, warfarin,
simvastatin, or probenecid
 The interaction of daptomycin
with tobramycin is unclear
 Linezolid is not an inducer of
CYP450 and is not expected to
affect other drugs metabolized
by these enzymes
 The pharmacokinetics of
linezolid were not altered when
coadministered with
aztreonam or gentamicin;
coadministration with rifampin
resulted in 21% decrease in
linezolid Cmax
 Linezolid is a reversible,
non-selective inhibitor of
monoamine oxidase and has
potential for interaction with
adrenergic and serotonergic
agents
 Binds to the artificial phospholipid
surfaces added to common
anticoagulation tests
 Interferes with urine qualitative
dipstick protein assays, as well as
quantitative dye methods
Precautions/warnings*  Monitor renal function in elderly
patients. Higher exposure in
elderly subjects is mainly
attributed to age-related
changes in renal function
 Seroconversion from a
negative to a positive direct
Coombs test result occurred in
10.8% and 4.4% of patients
receiving Teflaro and
comparator drugs,
respectively, in the four pooled
phase III clinical trials. If anemia
develops during or after ther-
apy, a diagnostic work-up for
drug-induced hemolytic
anemia should be performed
and consideration given to
discontinuation of ceftaroline
 In patients with renal
insufficiency, both renal
function and CPK should be
monitored more frequently
 Eosinophilic pneumonia has
been reported in patients
taking daptomycin
 Myelosuppression (including
anemia, leukopenia, pancyto-
penia, and thrombocytopenia)
has been reported
 Linezolid should not be used in
patients taking products that
inhibit monoamine oxidase A
or B
 Linezolid should not be
administered to patients with
uncontrolled hypertension,
pheochromocytoma, thyrotox-
icosis, or patients taking any of
the following types of
medications: directly and indi-
rectly acting sympathomimetic
agents, vasopressive agents,
or dopaminergic agents
 Linezolid should not be admin-
istered to patients with carci-
noid syndrome or patients
taking any of the following
medications: serotonin reup-
take inhibitors, tricyclic antide-
pressants, serotonin 5-HT1
receptor agonists, meperidine
or buspirone
 Lactic acidosis, peripheral and
optic neuropathy, and convul-
sions have been reported with
use of linezolid
 Avoid use during pregnancy unless
potential benefit to patient outweighs
potential risk to fetus
 New-onset or worsening renal
impairment
 Decreased efficacy noted with
moderate/severe baseline renal
impairment
 Rapid i.v. infusions of glycopeptides
can cause ‘‘Red-man syndrome’’-
like reactions. Administer over at
least 60 min to minimize reactions
 Caution is warranted when pre-
scribing telavancin to patients taking
drugs known to prolong the QT
interval
 Interferes with some laboratory
coagulation tests, including
prothrombin time, international
normalized ratio, and activated
partial thromboplastin time
i.v. = intravenous; q12h = every 12 hours; CPK = creatinine phosphokinase; Cmax = maximum plasma concentration; CrCL = creatinine clearance; CYP450 = cytochrome P450;
p.o. = oral.
* Additional warnings/contraindications:Clostridiumdifficile-associated diarrhea (CDAD) has been reportedwith use of nearly all antibacterial agents, andmay range in severity frommild
diarrhea to fatal colitis. Serious hypersensitivity reactions have been reportedwith b-lactam antibiotics. As with other antibacterial drugs, usemay result in overgrowth of non-susceptible
organisms, including fungi.
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e402 G. J. Moran et al.concentrations (15–20 mg/L) are recommended to
optimize vancomycin pharmacodynamics, improve
tissue penetration, and prevent resistance development;
however, higher rates of nephrotoxicity may be
a concern with trough concentrations >15 mg/L (46).
Because attainment of a vancomycin area under the
curve/MIC of $400 is unlikely in patients who have
S. aureus infections with MICs at the high end of the
susceptible range, antibiotics other than vancomycin
should be considered when vancomycin MIC values are
$2 mg/L (34,35). The IDSA MRSA treatment
guidelines note that for most patients with ABSSSI who
have normal renal function and are not obese, the
traditional vancomycin dose of 1 g every 12 h is
adequate and trough monitoring is not required (29).
Management of ABSSSI: Newer Therapeutic Options
Initial empiric therapy for ABSSSI is based on prediction
of the most likely pathogens and should be guided by
local antimicrobial susceptibility patterns (1,18,47,48).
Although CA-MRSA is resistant to available oral
b-lactams and many macrolides and fluoroquinolones,
most strains are susceptible to trimethoprim/sulfamethoxa-
zole, clindamycin, and tetracyclines such as doxycycline
and minocycline (2,15,18). Susceptibility to clindamycin
or doxycycline/minocycline is variable depending on
region; resistance to trimethoprim-sulfamethoxazole has
been reported rarely (2,18,49). For suspected
polymicrobial ABSSSI, treatment should include coverage
of enteric Gram-negative and anaerobic pathogens.
Intravenous (i.v.) antibiotic therapy may be considered
in the context of severe disease, rapid progression, indica-
tion of systemic illness, or when incision and drainage
is not possible or is ineffective (18,50). Although
vancomycin remains one of the most frequently used
i.v. antimicrobials for the treatment of serious Gram-
positive infections in the US, development of resistance
and other concerns noted previously underscore the
need for antibiotics with activity against MRSA. Several
i.v. antimicrobials with MRSA activity are approved for
treatment of ABSSSI, including ceftaroline fosamil,
daptomycin, linezolid, and telavancin (Table 2)
(51–54). Although tigecycline is indicated for ABSSSI,
data from clinical trials suggest emergence of resistant
isolates, a high incidence of adverse events, and an
increased risk of mortality with tigecycline treatment
(55,56). The US Food and Drug Administration (FDA)
has indicated that alternatives to tigecycline should be
considered in patients with serious infections due to an
increased risk of mortality compared with other drugs
used to treat such infections (57).
Traditionally, skin infections were characterized into
two general categories: 1) uncomplicated skin and skinstructure infections and 2) complicated skin and skin
structure infections (also termed complicated skin and
soft tissue infections). To standardize terminology and
define end points to be used in support of drugs seeking
indications for treatment of skin infections, the FDA re-
leased a draft document on ‘‘Acute Bacterial Skin and
Skin Structure Infections: Developing Drugs for Treat-
ment’’ in 2010, which provides guidance on the design
of clinical trials for systemic drugs to treat ABSSSI
(58). ABSSSI includes cellulitis/erysipelas, wound infec-
tions, major cutaneous abscess, and burn infections, in
which a reliable estimate of treatment effect of the antibi-
otic can be described for non-inferiority or superiority
trial designs. The hallmark characteristic of the condi-
tions included in the ABSSSI definition is infection ac-
companied by redness, edema, or induration extending
to a minimum surface area of 75 cm2. A superiority trial
design is recommended in adults and children with milder
skin infections (minor cutaneous abscesses and impetigo)
for which a treatment effect of the antibacterial therapy
has not been characterized. Previously, non-inferiority
trials in ABSSSI used the test-of-cure (TOC) visit as
the time point for evaluating clinical cure. Current regu-
latory guidance recommends that ABSSSI trials evaluate
clinical response, defined as cessation of lesion spread
and resolution (or absence) of fever, at 48–72 h after ini-
tiating therapy as the primary end point for clinical trials.
Because the FDA guidance was released in 2010, most
published clinical trials evaluating the efficacy of antibi-
otics for skin infections do not meet all of the current cri-
teria. Thus, specific eligibility criteria are provided for the
ABSSSI studies described in the next section and should
be considered when evaluating results from clinical trials.
Ceftaroline fosamil. Ceftaroline, the active form of cef-
taroline fosamil, is a broad-spectrum cephalosporin
with potent activity against MRSA. Ceftaroline exerts
rapid bactericidal activity by binding to key penicillin-
binding proteins (PBPs), with enhanced binding affinity
for the PBPs of several resistant pathogens, including
MRSA and penicillin-resistant Streptococcus pneumo-
niae (59,60). Ceftaroline exhibits high affinity for
staphylococcal PBPs 1, 2, and 3, particularly for MRSA
PBP 2A (61,62). In vitro, ceftaroline has potent
bactericidal activity against S. aureus, including
vancomycin-intermediate, -heteroresistant, and -resistant
strains and daptomycin-non-susceptible isolates (59,
63–67). For MRSA, the majority of isolates in
microbiologic studies were inhibited by ceftaroline
MIC90 of #1 mg/L (4,65,66,68). International
surveillance conducted in 2008 showed that ceftaroline
was highly active against pathogens associated with
ABSSSI, with low MIC values for MRSA isolates in
both the US and Europe (4). Ceftaroline has in vitro
Acute Bacterial Skin Infections e403activity against common Gram-negative bacteria, includ-
ing Haemophilus influenzae (including b-lactamase-pos-
itive isolates), non-extended-spectrum b-lactamase-
producing Klebsiella pneumoniae, and Escherichia coli,
but not Pseudomonas aeruginosa (63). Ceftaroline has
in vitro activity against specific anaerobic bacteria, in-
cluding Clostridium species, but not including Bacter-
oides fragilis or Clostridium difficile (69,70).
Ceftaroline fosamil may be considered for empiric
monotherapy when polymicrobial infections are
suspected. Multi-step resistance selection studies indicate
that resistance to ceftaroline is expected to be limited
(71,72).
Two multi-center, double-blind, randomized clinical
trials evaluated the efficacy of ceftaroline in ABSSSI
(73–75). The Ceftaroline versus Vancomycin in Skin
and Skin-Structure Infection (CANVAS 1 and 2) trials en-
rolled 1378 adult patients with ABSSSI requiring i.v.
therapy who were randomly assigned to receive ceftaro-
line fosamil 600 mg every 12 h (n = 693) or vancomycin
plus aztreonam (1 g each; aztreonam was discontinued if
a Gram-negative pathogen was not identified or sus-
pected) every 12 h (n = 685) for 5–14 days (73). Eligibil-
ity criteria included patients with three or more clinical
signs of infection (e.g., fever, purulent discharge, ery-
thema) and involvement of deep soft tissue or infections
requiring significant surgical intervention, such as
wounds with purulent drainage or $5 cm of cellulitis,
major abscess surrounded by$2 cm cellulitis, or celluli-
tis with surface area $10 cm2, or lower-extremity cellu-
litis or abscess in patients with diabetes or peripheral
vascular disease. Patients were excluded if they had cre-
atinine clearance (CrCL)# 30 mL/min; >24 h of antimi-
crobial therapy in the previous 96 h, unless there was
evidence of clinical and microbiologic failure after 48 h
of therapy; evidence of vancomycin- or aztreonam-
resistant pathogens, including known P. aeruginosa or
anaerobic infection; osteomyelitis or septic arthritis; nec-
rotizing fasciitis; human or animal bite; diabetic foot ul-
cer; decubitus ulcer; gangrene; burn covering > 5% of the
body; mediastinitis; or required surgical intervention that
could not be performed within 48 h after initiation of ther-
apy. Clinical cure was assessed at the TOC visit, which
occurred 8–15 days after the last dose of study drug. Ad-
ditionally, relevant data were collected during the study
for assessment of clinical response at day 3 (76).
Integrated analysis showed that disease severity was
consistent between the two groups, with cellulitis, major
abscess, and infected wound accounting for the majority
of infections. S. aureus was the most common pathogen
isolated, with MRSA accounting for 40% of infections in
the ceftaroline group and 34% in the vancomycin plus
aztreonam group. Ceftaroline fosamil was non-inferior
to vancomycin plus aztreonam in treated patients withABSSSI caused by Gram-positive and -negative patho-
gens. The clinical cure rate at TOC was 91.6% for cef-
taroline, compared with 92.7% with vancomycin plus
aztreonam in the clinically evaluable (CE) population
and 92.7% for ceftaroline vs. 94.4% for vancomycin
plus aztreonam in the microbiologically evaluable
(ME) population. The clinical cure rate for MRSA was
93.4% and 94.3%, respectively. The clinical response
rate (cessation of infection spread and absence of fever)
on day 3 was 74.0% (296/400) in patients treated with
ceftaroline fosamil, compared with 66.2% (263/397) in
patients who received vancomycin plus aztreonam, indi-
cating a numerically higher early clinical response with
ceftaroline fosamil monotherapy (difference 7.8%;
95% confidence interval [CI] 1.3–14). Susceptibility
testing showed that 96.8% of all isolates evaluated in
the CANVAS trials were inhibited at ceftaroline MIC
of 2 mg/L (59).
Consistent with the safety profile associated with the
cephalosporin class, ceftaroline is well tolerated. Inte-
grated safety summary of the CANVAS studies showed
that the incidence of serious adverse events was 4.3%
with ceftaroline and 4.1% with vancomycin plus aztreo-
nam, and the majority of patients (>75%) had either no
or mild treatment-emergent adverse events (TEAEs)
(77). The most common TEAEs reported with ceftaroline
included nausea, headache, diarrhea, and pruritus.
Daptomycin.Daptomycin is a cyclic lipopeptide antibiotic
with activity against a wide spectrum of Gram-positive
organisms, including MRSA (78,79). Daptomycin exerts
bactericidal activity in a unique concentration-
dependent manner by disrupting cell-membrane function
via calcium-dependent binding. It has excellent in vitro
bactericidal activity against MRSA (51,80,81).
Surveillance analysis of data collected from 32 US
medical centers from 2005 to 2010 showed that
daptomycin maintained a 99.94% susceptibility rate for
MRSA (82). Among MRSA, only 0.11% of isolates
were not susceptible to daptomycin, and there was no
trend toward higher resistance during the study. Treatment
failures associated with daptomycin-non-susceptible iso-
lates have been reported, and resistance was induced by
serial passagewith increasing concentrations of daptomy-
cin (80,83,84). Although the mechanism of resistance to
daptomycin is unclear, genetic mutations have been
described in S. aureus isolates with daptomycin MICs >
1 mg/L. There is evidence of cross-resistance with vanco-
mycin. Elevated vancomycin MICs may be associated
with similar shifts in daptomycin MICs, although in-
creased vancomycin MICs for S. aureus have not been
shown to be a predictor of daptomycin failure (85). Dap-
tomycin is not active against aerobic or anaerobic Gram-
negative bacteria.
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treatment of ABSSSI (86–88). Two randomized,
controlled, phase 3 clinical trials evaluated the efficacy
of daptomycin 4 mg/kg every 24 h for 7–14 days
compared with conventional antibiotics (semi-synthetic
penicillins 4–12 g/d or vancomycin 1 g every 12 h) in
1092 patients with ABSSSI (86). Patients with infections
caused by Gram-positive organisms, including wound in-
fections (surgical wounds, trauma, and bites), major ab-
scesses, infected diabetic ulcers, and ulcers due to other
causes (vascular insufficiency) were included in the
study. Patients with minor or superficial infections (e.g.,
simple abscesses), perirectal abscesses, gangrene, multi-
ple infected ulcers at distant sites, third-degree burns, or
known bacteremia at enrollment were excluded, as were
those who required amputations or had concomitant in-
fections at another site (e.g., osteomyelitis, endocarditis,
septic arthritis). Clinical success, determined at the TOC
visit (6–20 days after receipt of last dose), was based on
resolution of signs and symptoms such that no further an-
tibiotic treatment was required. MRSA was isolated in
9.3% and 10% of the daptomycin and comparator groups,
respectively. Daptomycin had a clinical success rate of
83.4% compared with 84.2% with the comparator treat-
ment group among the 902 CE patients; similar rates
were reported in the ME patients. Among patients suc-
cessfully treated with i.v. therapy alone, patients receiv-
ing daptomycin had shorter duration of therapy; 63% of
daptomycin-treated patients, compared with 33% in the
comparator group, required only 4–7 days of therapy
(p < 0.0001).
In an open-label, prospective study, 53 patients with
ABSSSI at risk for MRSAwere treated with daptomycin
4 mg/kg/d for 3–14 days and compared with 212 matched
historical controls who received at least 3 days of vanco-
mycin therapy at a dose sufficient to achieve a trough con-
centration of 5–20 mg/L (87). Eligible patients included
adults with ABSSSI (specifics not reported) who had at
least three local signs and symptoms of infection, such
as pain, tenderness, swelling, erythema, or discharge. Pa-
tients were excluded if they had gas gangrene, progres-
sive necrotizing infections, osteomyelitis, documented
bacteremia or endocarditis, pathogens identified as non-
susceptible to daptomycin, requirement of non-study an-
tibiotics active against S. aureus for other reasons during
the study, 24 h or more of treatment with another i.v. anti-
staphylococcal antibiotic, infections associated with
prosthetic hardware, weight of more than 150 kg or <40
kg, estimated CrCL < 30 mL/min, life expectancy of <3
months, burns over > 30% of body surface area, and preg-
nant or nursing women.MRSAwas isolated in 42% of pa-
tients in the daptomycin group and 75% of patients in the
vancomycin group (p < 0.001). A higher proportion of pa-
tients treated with daptomycin achieved clinical success,defined as absence of all pretreatment signs and symp-
toms of infection or no continued antibiotic therapy
deemed necessary, by day 3 (90% daptomycin vs. 70%
vancomycin; p < 0.01) and day 5 (98% daptomycin vs.
81% vancomycin; p < 0.01).
A retrospective analysis of data from the Cubicin Out-
comes Registry and Experience 2004 registry, which in-
cludes 45 institutions, assessed clinical response to
daptomycin therapy in 165 patients with ABSSSI (88).
Patients were eligible for inclusion in the registry if
they had infections involving deep soft tissue; infections
requiring surgical intervention (ulcers, burns, and major
abscesses); infections in patients with significant underly-
ing disease states that complicate response to antibiotic
treatment; and infections typically requiring i.v. therapy,
such as non-surgical wounds, major abscesses, surgical-
site infections, diabetic foot ulcers, and non-diabetic
ulcers. Patients with uncomplicated cellulitis, simple ab-
scess, erysipelas, furuncles, acne, and impetigo were ex-
cluded. The majority of patients were treated with
daptomycin 4–6 mg/kg once daily, and 86.7% (n = 143)
of patients had culture-confirmed MRSA infections.
Clinical success, defined as an outcome of cure (resolu-
tion of clinical signs and symptoms or no additional
need for antibiotic therapy) or improved (partial resolu-
tion of clinical symptoms or need for additional antibiotic
therapy at end of therapy), was achieved by 89.7% of pa-
tients with MRSA and 85% with MSSA infections. In the
group that had a successful outcome, median time to clin-
ical response was 3.5 days in patients with MRSA and 2.0
days in thosewithMSSA infections. Total median days of
therapy with daptomycin was 13 days in the patients with
MRSA and 11 days in patients with MSSA.
Myopathy, manifesting as muscle weakness and pain,
and associated with elevated creatine phosphokinase
(CPK) concentrations, has been reported with daptomy-
cin, particularly with higher doses (89–92). In clinical
trials, the most commonly reported adverse events with
daptomycin included constipation, nausea, injection-site
reactions, headache, diarrhea, insomnia, rash, vomiting,
abnormal liver function tests, pruritus, elevated CPK,
fungal infection, urinary tract infection, hypotension, re-
nal failure, dizziness, anemia, and dyspnea (51). In 2010,
the FDA issued a warning about the potential for develop-
ment of eosinophilic pneumonia during treatment with
daptomycin (93).
Linezolid. Available in both i.v. and oral formulations
with approximately 100% oral bioavailability, linezolid
is a synthetic oxazolidinone that inhibits initiation of pro-
tein synthesis by selectively binding to the 50S ribosomal
unit (94,95). Overall concentration of linezolid in soft
tissues is similar to plasma concentrations (42). Linezolid
exerts bacteriostatic activity against Gram-positive
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cluding MRSA, VISA, and VRSA (96,97). Surveillance
data since 2009 indicate that linezolid remains active
against >99% of S. aureus strains, with very low rates
of resistance noted (0.34% overall) (64,98,99). Cases of
linezolid resistance have been reported and may be
associated with prolonged drug exposure as well as
prior linezolid administration (98,100). Resistance to
linezolid is likely mediated by mutation of 23S rRNA
(101). Linezolid is not active against aerobic or anaerobic
Gram-negative pathogens.
Numerous studies have evaluated the efficacy of line-
zolid vs. vancomycin or other comparators in the man-
agement of ABSSSI, with variable outcomes due to
inconsistent reporting of the clinical and microbiologic
efficacy data (102–107). A randomized, open-label,
multi-center trial compared linezolid 600 mg every 12 h
(n = 592) with vancomycin 1 g every 12 h (n = 588) for
7–14 days (duration of treatment could extend from 4–
21 days) in patients with Gram-positive-complicated
ABSSSI (104). Entry criteria included patients with sus-
pected or proven MRSA infections involving substantial
areas of skin or deeper soft tissues, such as cellulitis, ab-
scesses, infected ulcers, or burns (<10% of total body sur-
face). Exclusions included patients with Gram-negative
infections, osteomyelitis, endocarditis, meningitis, septic
arthritis, necrotizing fasciitis, gas gangrene, infected de-
vices that were not removed, superficial skin infections,
and hypersensitivity to the study medications. Clinical
cure was defined as complete resolution of all pre-
therapy clinical signs and symptoms of infection (eg,
body temperature and white blood cell count). In the
intent-to-treat population, 92.2% of patients treated
with linezolid were clinically cured at the TOC visit (7
days after the end of therapy), compared with 88.5% of
patients treated with vancomycin (p = 0.057). MRSA
(42%) was the most commonly isolated pathogen at base-
line. In the subset of patients withMRSA infections in the
ME population, linezolid outcomes were superior to van-
comycin at the TOC visit (88.6% [124/140] vs. 66.9%
[97/145], respectively; p < 0.001). Symptom scores re-
turned to baseline at day 4 in 70% of linezolid-treated pa-
tients compared with 62% in the vancomycin-treated
group (p = 0.044). However, treatment duration was lon-
ger in the linezolid group than for patients receiving van-
comycin (overall mean treatment duration was 11.8 6
4.9 days for linezolid, compared with 10.9 6 5.3 days
for vancomycin; p < 0.004).
A meta-analysis identified five prospective, random-
ized, controlled open-label trials with a total of 2652 pa-
tients evaluating linezolid (n = 1361) and vancomycin
(n = 1291) in the treatment of MRSA-complicated
ABSSSI (107). In all trials, linezolid 600 mg was given
either i.v. or orally every 12 h and vancomycin1000 mg i.v. was given every 12 h; treatment duration
ranged from 4 to 28 days. Efficacy outcomes were re-
ported at the TOC visit (7–21 days after the end of treat-
ment) in all studies. The modified intent-to-treat (MITT)
population had culture-confirmed Gram-positive infec-
tion (S. aureus) at baseline and success was defined as
eradication of the Gram-positive pathogen upon culture.
The MRSA-evaluable population met the MITT criteria
and had a positive culture forMRSA; success was defined
as eradication of MRSA upon culture. Clinical resolution
of infection in the CE population initially favored use of
linezolid (odds ratio [OR] 1.41; 95% CI 1.03–1.95), but
this result was no longer significant after removal of the
most heavily weighted study (OR 1.29; 95% CI 0.81–
2.05). In the MITT population, patients on linezolid
were more likely to achieve microbiologic eradication
compared with those on vancomycin treatment (OR
1.91; 95% CI 1.33–2.76). However, these differences
also were non-significant after sensitivity analyses
(MITT: OR 1.73; 95% CI 0.87–3.41). MRSA-evaluable
patients treated with linezolid (n = 289) were more likely
to achieve microbiologic eradication compared with
vancomycin-treated patients (n = 273) (OR 2.90; 95%
CI 1.90–4.41), an effect that remained significant with
sensitivity analysis (OR 2.24; 95% CI 1.26–3.99). There
was no difference in mortality between groups. A higher
proportion of patients treated with linezolid, compared
with vancomycin treatment, reported diarrhea (119/
1361 vs. 52/1291), nausea (102/1361 vs. 46/1291), and
thrombocytopenia (52/1121 vs. 8/1071).
In phase 3 clinical trials, adverse events were signifi-
cantly more common in patients treated with linezolid
than in comparator groups, although discontinuation rates
were comparable (108,109). Gastrointestinal adverse
events, including nausea and diarrhea, and headache are
the most common adverse events reported with
linezolid. Prolonged use of linezolid (>28 days) has
been associated with various adverse events that may
affect clinical utility, including peripheral and
optical neuropathy, hematological abnormalities, and
hyperlactatemia (108,109) (Table 2). More than 50 cases
of neuropathy associated with linezolid therapy have
been reported, and development of neuropathy warrants
discontinuation of therapy; recovery from peripheral neu-
ropathy may be limited (109). Myelosuppression, includ-
ing thrombocytopenia and anemia, has been observed
when linezolid is administered for longer than 14 days,
although decreases in platelet count may occur earlier
in some patients (104,107,110,111). The incidence of
linezolid-related thrombocytopenia is likely higher than
the 2.4% reported in early clinical trials, and certain pa-
tient populations, such as those with malignancies, may
be at increased risk (109). Although no specific treatment
exists for linezolid-mediated thrombocytopenia, platelet
e406 G. J. Moran et al.counts typically return to normal after discontinuation of
therapy. In the case of anemia, patients can be managed
with transfusions, and hemoglobin normalizes after dis-
continuation of the drug. Linezolid has the potential for
significant drug interactions with serotonin modulators
(e.g., selective serotonin reuptake inhibitor; serotonin
norepinephrine reuptake inhibitor) that may lead to sero-
tonin syndrome, which manifests with marked hyperten-
sion, tachycardia, hyperthermia ($40C), and general
muscle rigidity (109,112). Linezolid may also interact
with sympathomimetic agents (e.g., diphenhydramine),
manifesting as significantly increased blood pressure.
An alternative antibiotic should be considered in
patients taking these medications.
Telavancin. Telavancin is a semi-synthetic, vancomycin-
derived lipoglycopeptide that inhibits cell-wall synthesis
by binding to peptidoglycan chain precursors, causing
cell-membrane depolarization (113). Telavancin exerts
concentration-dependent, bactericidal activity against
Gram-positive pathogens, including drug-resistant staph-
ylococci (MRSA and hVISA), streptococci, and entero-
cocci (114,115). Telavancin demonstrated potent in vitro
activity when tested against 24,017 Gram-positive iso-
lates, including S. aureus, coagulase-negative Staphylo-
coccus spp., and various Streptococcus spp. from North
America, LatinAmerica, Europe, andAsia (115). In all re-
gions, telavancin was highly active against S. aureus.
Analysis of 1530 aerobicGram-positive isolates identified
during clinical studies using telavancin for the treatment
of ABSSSI indicated that all evaluated staphylococcal,
streptococcal, and enterococcal isolates were inhibited
by #1 mg/L of telavancin (116). Telavancin seems to
have low potential for resistant mutant selection (117).
Evaluation of drug concentrations in skin blister fluid in
eight healthy volunteers indicated that telavancin
achieves sufficient levels in tissue to eradicate Gram-
positive pathogens (118). Telavancin is not active against
aerobic or anaerobic Gram-negative pathogens.
The efficacy of telavancin in the treatment of ABSSSI
was evaluated in several clinical trials (119–123). Two
identical, randomized, double-blind, active-controlled
phase 3 clinical trials (Assessment of TeLAvancin in
Skin and skin structure infections [ATLAS] 1 and 2) eval-
uated the efficacy of telavancin 10 mg/kg i.v. every 24 h
compared with vancomycin 1 g i.v. every 12 h for 7–14
days in 1867 patients with ABSSSI caused by suspected
or confirmed Gram-positive organisms (120). Eligible pa-
tients had cellulitis, major abscess requiring surgical
drainage, infected wound or ulcer, or infected burn. Ex-
cluded were patients who had prior antibiotic therapy
for >24 h within 7 days of enrollment, osteomyelitis, nec-
rotizing fasciitis, chronic diabetic foot ulcers, gangrene,
burns of >20% body surface, mediastinitis, uncompli-cated ABSSSI, absolute neutrophil count < 500 cells/
mm3, human immunodeficiency virus infection, uncom-
pensated heart failure, a QTc interval > 500 ms, or a re-
quirement for concomitant administration of agents
containing cyclodextrin. The primary efficacy end point
was clinical response at TOC (7–14 days after the last
dose of medication). Clinical cure was defined as resolu-
tion of clinically significant signs and symptoms of infec-
tion or improvement to such an extent that no further
antibiotic therapy was necessary. The baseline pathogen
was considered eradicated at end of therapy or TOC if
not detected by culture, or presumed to be eradicated if
the patient’s clinical response was cure. In the CE popula-
tion at the TOC visit, clinical cure was achieved in 88.3%
(658/745) of patients treated with telavancin and 87.1%
(648/744) in the vancomycin group. In CE patients with
MRSA infections, the clinical cure rate was 90.6% (252/
278) with telavancin and 86.4% (260/301) with vancomy-
cin. Microbiologic response rate was 89.9% (250/278)
and 85.4% (257/301) for telavancin and vancomycin, re-
spectively, in patientswho hadMRSA isolated at baseline.
In the telavancin group, TEAEs included taste distur-
bance, nausea, and vomiting. Increased serum creatinine
concentration of >1.5 mg/dL and >50% above baseline
was noted more frequently in the telavancin group
(6.3%) than in the vancomycin group (2.2%; p < 0.05).
Although renal dysfunction associated with telavancin
seems reversible upon cessation of therapy, renal function
should be monitored during therapy and for several days
after discontinuation. Telavancin should be used cau-
tiously in patients with pre-existing renal conditions, hy-
pertension, or diabetes, and in patients taking other
medications that may affect renal function (e.g., amino-
glycosides). Factors associated with development of
telavancin-mediated acute renal insufficiency include
prior supratherapeutic vancomycin trough levels (>20
mg/L), high body mass index, and use of i.v. contrast
dye before telavancin therapy (124). QTc interval prolon-
gation was reported with telavancin therapy, although no
associated cardiac adverse events were noted in the AT-
LAS trials. Telavancin should be used cautiously with
other agents such as fluoroquinolones or antidysrhyth-
mics that may prolong the QTc interval (113).
Drugs in development. Several investigational agents in
clinical development show promise for the treatment of
ABSSSI. Dalbavancin is a semi-synthetic lipoglycopep-
tide with long half-life and bactericidal activity against
Gram-positive cocci, including MRSA (125–127). In
a phase 3 study evaluating patients with ABSSSI (major
abscesses, major burns, traumatic or surgical wound
infections, and deep skin-structure infections, such as ul-
cerating cellulitis), dalbavancin 1000mg given i.v. on day
1 and 500 mg given on day 8 (n = 571) was comparable to
Acute Bacterial Skin Infections e407linezolid 600mg (either i.v. or oral) administered every 12
h for 14 days (n = 283) (128). Oritavancin is another inves-
tigational lipoglycopeptide currently in development
for management of ABSSSI caused by multi-drug-
resistant, Gram-positive pathogens, including MRSA
(127). Clinical trial data indicate that oritavancin is effica-
cious in treating ABSSSI caused by Gram-positive patho-
gens (129,130). Omadacycline (PTK796) is a novel
aminomethylcycline that is a member of the tetracycline
family of antibiotics with a broad spectrum of activity.
In vitro data indicate that omadacycline is active against
Gram-positive pathogens, including CA-MRSA and
b-hemolytic streptococci, as well as pathogens resistant
to tetracycline. In phase 2 clinical trials, omadacycline
was active against S. aureus, including MRSA, with an
MIC90 of 0.25 mg/L, and was comparable to linezolid in
treatment of patients with ABSSSI (131,132).
Rapid Testing for MRSA
Obtaining culture specimens to document the presence of
MRSA and for susceptibility testing is an important step
to guide selection of antimicrobial therapy (2). Histori-
cally, laboratory detection methods for MRSA and
S. aureus from wounds or blood cultures required
48–72 h for culture. Recently, several rapid detection as-
says have been developed that utilize real-time polymer-
ase chain reaction to identify MRSAwithin hours instead
of days, and many of these assays are used to screen for
MRSA carriage (133,134). Rapid detection of MRSA
from wound specimens is particularly useful in patients
with ABSSSI at greater risk for treatment failure, such
as individuals who are immunocompromised. The
recent availability in the US of a rapid-detection assay
to identify MRSA from wound specimens allows for
better-informed therapeutic decisions in the ED. The
Xpert MRSA/SA skin and soft tissue infection (SSTI)
assay (Cepheid Inc., Sunnyvale, CA) is approved for
rapid detection (within 1 h) of MRSA and S. aureus
from wounds. In a multi-center evaluation that included
a total of 114 wound specimens, the MRSA/SA SSTI as-
say performed with a sensitivity of 97.1% for MRSA de-
tection, with 96.2% specificity, 91.9% positive predictive
value, and 98.7% negative predictive value; similar per-
centages were noted for S. aureus (135). Overall agree-
ment between the assay and standard culture was 96.5%.
Rapid identification and differentiation of MRSA from
wound specimens may allow clinicians to more expedi-
ently initiate appropriate antimicrobial therapy in the ED.
Outpatient Parenteral Antimicrobial Therapy
Patients with ABSSSI who require i.v. antibiotics but do
not need hospitalization for 24-h care may be candidatesfor treatment in the outpatient setting. The practice of
OPAT has expanded in the US and is a good option that
can prevent or shorten hospitalizations, reduce overall
treatment costs, decrease readmission rates, and reduce
incidence of nosocomial infections (136–139). The
IDSA published comprehensive guidelines for OPAT in
2004, noting the effectiveness of OPAT for a variety of
infections, including ABSSSI (50,139,140). The
decision to hospitalize or utilize OPAT is based on
clinical assessment of infection severity and underlying
comorbidity. For example, patients with systemic
toxicity or rapidly progressive or worsening infections
despite antibiotic therapy would not be good candidates
for OPAT. When selecting antimicrobials for OPAT,
a number of factors should be considered,
including probable pathogens, pharmacodynamic and
pharmacokinetic properties of selected agents, dosing
schedules, toxicity profile, need for drug-level monitor-
ing, and drug stability (139). Although any antimicrobial
could theoretically be selected for OPAT, drugs with lon-
ger half-lives offer the advantage of once-daily adminis-
tration, which may reduce risk for complications (i.e.,
minimizes handling of the i.v. line), improved patient
compliance, and lessened disruption of daily activities
(138,139,141). Tolerability is another important issue
when considering OPAT. Some agents, such as
vancomycin, are more likely to cause phlebitis, whereas
cephalosporins and aminoglycosides have low potential
for phlebitis (142).
CONCLUSION
CA-MRSA has emerged as a predominant cause of
ABSSSI in the US, and ED visits for ABSSSI have risen
in direct correlation. The increasing prevalence of CA-
MRSA is concerning and has led the IDSA and other
organizations to recommend empiric coverage of CA-
MRSA for patients with ABSSSI. Several newer i.v.
antimicrobials with MRSA activity, including ceftaroline
fosamil, daptomycin, linezolid, and telavancin, are avail-
able for managing ABSSSI in the ED and may help meet
the clinical demand for alternative antistaphylococcal
drugs.
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1. Why is this topic important?
Community-acquired methicillin-resistant Staphylo-
coccus aureus (CA-MRSA) is the predominant cause of
purulent acute bacterial skin and skin structure infections
(ABSSSI) in the United States. Patients with ABSSSI
commonly present to Emergency Departments where
a wide spectrum of disease severity may be encountered.
2. What does this review attempt to show?
This review focuses on recent studies and recommenda-
tions for management of ABSSSI in the CA-MRSA era.
3. What are the key findings?
Since the 2005 Infectious Diseases Society of America
(IDSA) guidelines for the management of ABSSSI, em-
piric coverage of CA-MRSA for purulent ABSSSI is
now recommended. Several intravenous antibiotics with
expanded MRSA coverage, including ceftaroline fosamil,
daptomycin, linezolid, and telavancin, may be considered
for management of ABSSSI. Further, availability of rapid
MRSA detection assays from skin and soft-tissue swabs
may facilitate earlier selection of targeted therapy.
4. How is patient care impacted?
This article offers a review of significant developments
since the most recent IDSA guidelines for the manage-
ment of ABSSSI, including a review of recent studies
and recommendations for managing CA-MRSA.
